Article

FDA approves prostate cancer drug delivery system

The FDA has approved Mixject, a new delivery system for triptorelin pamoate (Trelstar), a palliative treatment for advanced prostate cancer. Mixject combines triptorelin depot, 3.75 mg, and long-acting triptorelin, 11.25 mg, with new features that make preparation, administration, and disposal easier, according to Watson Pharmaceuticals, the manufactuer of triptorelin.

The FDA has approved Mixject, a new delivery system for triptorelin pamoate (Trelstar), a palliative treatment for advanced prostate cancer. Mixject combines triptorelin depot, 3.75 mg, and long-acting triptorelin, 11.25 mg, with new features that make preparation, administration, and disposal easier, according to Watson Pharmaceuticals, the manufactuer of triptorelin.

These new features include a smaller, 21-gauge needle for improved patient comfort, reconstitution without the use of a needle, and a shield covering the needle both before and after drug administration. The system is specifically designed to encourage compliance with OSHA regulations within the medical community.

Related Videos
Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Timothy Lyon, MD, on recent change to outpatient complications metric in urology rankings
Timothy Lyon, MD, on recent change to outpatient complications metric in urology rankings
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Checkpoint Inhibitors for Treatment of NMIBC
Checkpoint Inhibitors for Treatment of NMIBC
Communication of Treatment Options for High-Risk NMIBC
Communication of Treatment Options for High-Risk NMIBC
Jason Hafron, MD, considers the future for AI in urology
Jason Hafron, MD, considers the future for AI in urology
Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
3 experts are featured in this series.
Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
3 experts are featured in this series.
Subgroup Analyses and Clinical Insights in Metastatic Hormone-Sensitive Prostate Cancer Treatment
Related Content
Hospital waiting room with reception counter at medical facility | Image Credit: © visoot - stock.adobe.com
April 5th 2025

Vaginal prolapse repair and sling surgery significantly reduce UUI

Christina M. Mezes, DO Catherine A. Matthews, MD
"The biggest message from this study is that 60% can expect resolution of UUI, simply by fixing the prolapse and placing a sling, which is not normally indicated for UUI," according to Christina M. Mezes, DO, and Catherine A. Matthews, MD.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Drug Costs | Image Credit: © pixelrobot - stock.adobe.com
April 4th 2025

Cutting drug costs for patients: key takeaways for urologists

Benjamin Pockros, MD, MBA
"The Inflation Reduction Act was a major step in the right direction. The question now is going to be, are commercial insurers going to follow Medicare and enact the same cap that they have as well," says Benjamin Pockros, MD, MBA.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: @ Dr_Microbe - stock.adobe.com
April 3rd 2025

CD46-targeting ADC shows encouraging clinical activity in mCPRC

Hannah Clarke
The company plans to initiate the phase 2 monotherapy trial by mid-year.
Faceless view of senior man talking to doctor in bright light while taking notes on clipboard | Image Credit: © DragonImages - stock.adobe.com
April 3rd 2025

Kiran Sury, MD, on implementing ProACT for incontinence

Kiran Sury, MD
"In terms of making it a safe, highly reliable operation, if you're comfortable with slings and sphincters, you are very well positioned to learn this surger," says Kiran Sury, MD.
© 2025 MJH Life Sciences

All rights reserved.